SCHEMBL19970846

SCHEMBL19970846

COC(=O)c1ccc(COc2ccccc2CN2CCN(C(=O)c3ccc4nc(-c5ccccc5)[nH]c4c3)CC2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.50
PDE4A P27815 1/20 0.49
PDE4B Q07343 1/20 0.49
PDE4C Q08493 1/20 0.49
PDE4D Q08499 1/20 0.49
ACACB O00763 1/20 0.49
CHEK2 O96017 7/20 0.47
HDAC6 Q9UBN7 2/20 0.47
HDAC3 O15379 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
BCHE P06276 2/20 0.46
ACHE P22303 2/20 0.46
LMNA P02545 2/20 0.46
KDM4E B2RXH2 3/20 0.45
ALDH1A1 P00352 3/20 0.45
NPC1 O15118 1/20 0.45
PKM P14618 1/20 0.45
HPGD P15428 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19970844 0.94 LMNA (0.46) MGLLPDE4APDE4BPDE4CPDE4D
SCHEMBL19970796 0.93 ACACB (0.51) MGLLPDE4APDE4BPDE4CPDE4D
SCHEMBL19982681 0.92 HDAC6 (0.50) PDE4APDE4BPDE4CPDE4DCHEK2
SCHEMBL23843052 0.92 ACACB (0.47) PDE4APDE4BPDE4CPDE4DACACB
SCHEMBL19970732 0.90 ACACB (0.52) PDE4APDE4BPDE4CPDE4DACACB
SCHEMBL23828686 0.87 LMNA (0.48) PDE4APDE4BPDE4CPDE4DCHEK2
SCHEMBL19970845 0.87 LMNA (0.44) MGLLPDE4APDE4BPDE4CPDE4D
SCHEMBL19970795 0.87 ACACB (0.45) MGLLACACBLMNAKDM4EALDH1A1
SCHEMBL19970887 0.85 HDAC6 (0.44) PDE4APDE4BPDE4CPDE4DACACB
SCHEMBL19970823 0.84 SLC2A1 (0.49) PDE4APDE4BPDE4CPDE4DCHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11479571-B2 Benzimidazol derivatives for treating filovirus infection CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2022-10-25 US disclosed
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION UNIVERSITE D'ORLEANS (FR) 2021-09-23 US disclosed
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION UNIVERSITE D'ORLEANS (FR) 2021-09-23 US disclosed
WO-2018050771-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-22 WO disclosed
EP-3296297-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-21 EP disclosed
EP-3296297-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION FIP1L1, ZC3HAV1, MAVS MGLL 2286/4885PDE4A 2727/4885PDE4B 2766/4885
US-11479571-B2 Benzimidazol derivatives for treating filovirus infection FIP1L1, ZC3HAV1, MAVS MGLL 2286/4885PDE4A 2727/4885PDE4B 2766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.